


**BOOK NOW TO SAVE
UP TO \$800**

March 26-28, 2019 | Boston, USA

www.as-immunetolerance.com



^{2nd} Antigen-Specific Immune Tolerance Drug Development

**Optimize Antigen-Specific Immune Tolerance
Induction Strategies, Accelerate Safe and
Effective Translation into the Clinic & Expand
Opportunities Through Combination Therapies**

Expert Speakers Including:



Amy Rosenberg
Supervisory Medical
Officer and Division
Director, Office of
Biotechnology Products
CDER/FDA



Antoon Van Oosterhout
VP & Head Allergic
Inflammation Discovery
Performance Unit
GSK



Gerald (Jerry) Nepom
Director
Immune Tolerance Network



Anne De Groot
CEO & CSO
EpiVax



Matthias von Herrath
Professor at the La Jolla
Institute for Allergy &
Immunology; VP of T1D R&D
Center Seattle
Novo Nordisk



Robert (Bob) Anderson
CSO
ImmusanT



Jack Ragheb
Senior Medical Fellow
for Immunology- Global
Patient Safety
Eli Lilly



Michael Boyne
VP of Product Development
& Analytics
Cour Pharmaceuticals



Kei Kishimoto
CSO
Selecta Biosciences

Proud To Partner With:

Topas  Therapeutics

ORION
BIOSCIENCE INC.

NEKTAR

Tel: +1 617 455 4188 Email: info@hansonwade.com

REGISTER HERE



2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019

Successfully Improve the Discovery of Novel Antigens, Optimize the Tolerance Delivery Systems & Accelerate the Translation of Safe & Effective Immune Tolerance Therapies into the Clinic with Solution Led Insights from the Fields of Allergy & Autoimmunity

As the race to generate compelling clinical data to prove the concept of antigen-specific immunotherapies gains momentum, the **2nd Antigen-Specific Immune Tolerance Drug Development Summit** returns to Boston in 2019 to help large pharma, biotech and academic researchers overcome the complexity of auto-immune mediated disorders, expand opportunities through combination strategies and undertake a more precise and antigen-specific approach to novel drug development.

Join your peers at the **2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019** and become central to leading industry conversations dedicated to overcoming the challenge of **discovering and defining monogenic and multigenic antigens** present in very complex diseases that do not replicate well in animal models and **improving tolerance delivery systems** in order to robustly **translate and generate human clinical data** to develop effective therapies for the unmet fields of allergy, transplantation and autoimmunity.

Why our speakers are looking forward to this summit?

“I look forward to presenting our new, unpublished research on Tregitopes to a gathering of my peers”

Anne De Groot, CEO & CSO, EpiVax

“Pulling together speakers from across the field of antigen-specific tolerance translation into a single focussed meeting is what excites me about this summit”

Ranjeny Thomas, Professor of Rheumatology at University of Queensland; Director, Dendright



100+
Attendees



7+
Hours of
Networking



3
Interactive
Workshops



23+
Real World
Case Studies

Why Attend the 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019?



1. Benchmark against the latest understandings of antigen-specific immune tolerance strategies as therapeutic targets in allergy and autoimmune diseases with insights from **Immune Tolerance Network, Eli Lilly & Dendright**



4. Increase your translational success rate with case studies on how to overcome challenges of animal model studies and identification/validation of human biomarkers from **Novo Nordisk, ImmusanT & Akston Biosciences**



2. Widen your expertise on identification & validation of novel targets & mechanism of actions for effective antigen-specific immune tolerance induction with insights from **GSK, EpiVax & University of Zurich**



5. Optimize your clinical trial strategy by hearing the latest insights from patient data of the most advanced antigen-specific immune tolerance clinical programs from **Selecta Biosciences, Cour Pharmaceuticals & ImmusanT**



3. Overcome key design and optimization challenges of antigen-specific delivery systems with insights from **Topas Therapeutics, SQZ Biotechnologies & Northwestern University**



6. Join the momentum to re-define the antigen-specific immune tolerance induction strategies & widen the opportunities through combination therapies with insights from **FDA, Provention Bio & ActoBio Therapeutics**

YOUR EXPERT SPEAKERS



Carla Greenbaum
Director- Diabetes
Program
**Benaroya Research
Institute**



Gerald (Jerry) Nepom
Director
**Immune Tolerance
Network**



David Wraith
Institute Director
of Immunology &
Immunotherapy and
Professor of Immunology
University of Birmingham



Amy Rosenberg
Supervisory Medical
Officer and Division
Director, Office of
Biotechnology Products
CDER/FDA



Ranjeny Thomas
Professor of Rheumatology
at University of
Queensland; Director
Dendright



Erika von Mutius
Professor of Pediatric
Allergology
**Dr. von Hauner Children's
Hospital**



Jack Ragheb
Senior Medical Fellow
for Immunology- Global
Patient Safety
Eli Lilly



Robert (Bob) Anderson
CSO
ImmusanT



Michael Boyne
VP of Product
Development & Analytics
Cour Pharmaceuticals



Julia Greenstein
VP- Research Strategy
JDRF



Antoon Van Oosterhout
VP & Head Allergic
Inflammation Discovery
Performance Unit
GSK



Anne De Groot
CEO & CSO
EpiVax



Timm Jessen
CEO
Topas Therapeutics



Roland Martin
Head- Department of
Neuroimmunology &
Multiple Sclerosis Research
Neurology Clinic
**University Hospital Zurich,
University of Zurich**



Charlotte Fribert
CEO
Toleranzi AB



Kei Kishimoto
CSO
Selecta Biosciences



Stephen Miller
Co-founder of Cour
Pharmaceuticals; Professor
of Microbiology-Immunology
**Northwestern University
Medical School**



Francisco Leon
CSO
Provention Bio



Pieter Rottiers
CEO
ActoBio Therapeutics



Finola Moore
Associate Director of
Immune Tolerance
SQZ Biotechnologies



Matthias von Herrath
Professor at the La Jolla
Institute for Allergy &
Immunology; VP of T1D
R&D Center Seattle
Novo Nordisk



David Alleva
Executive Director-
Immunotherapeutics
Akston Biosciences



Joshua Sestak
President & CSO
Orion BioScience



Simi Ahmed
Director, Research
JDRF



Andreas Lutterotti
MD; Assistant Professor-
Experimental Therapy
Research in Multiple
Sclerosis
University of Zurich



Yoav Messinger
Medical Director- Cancer
and Blood Disorders
**Children's Hospitals and
Clinics of Minnesota**



Xunrong Luo
Director-Translational
Research
**Duke Transplant Center,
Duke University**

WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED AT THE SUMMIT?

“I look forward to further exchanges with specialists in the field of Antigen-Specific Immune Tolerance, to deepen and broaden dialog started at the first Antigen-Specific Immune Tolerance Summit in Boston, which was quite illuminating”



Charlotte Fribert
CEO
Toleranzi AB

“This meeting will provide opportunities to network with key scientists, hear about the latest developments and state-of-the-art science in the field of immune tolerance”



Antoon Van Oosterhout
VP & Head Allergic Inflammation Discovery Performance Unit
GSK

“This meeting is an ideal opportunity to gain insight into new tolerance strategies and obtain an overview of the existing field”



Jack Ragheb
Senior Medical Fellow for Immunology- Global Patient Safety
Eli Lilly

“I look forward to participating at this summit as cross-disease and cross-discipline exchanges are critical if we are to make disease-modifying therapy a reality in type 1 diabetes”



Carla Greenbaum
Director- Diabetes Program
Benaroya Research Institute

“I look forward to exchanging ideas and concepts on immune tolerance across the different perspectives from academia, biotech and pharma”



Andreas Lutterotti
MD; Assistant Professor- Experimental Therapy Research in Multiple Sclerosis
University of Zurich

“The meeting is an excellent event for networking but also an opinion generator/former for developing these novel therapeutics clinically in the exciting field of antigen-specific immune tolerance induction”



Timm Jessen
CEO
Topas Therapeutics

CONFERENCE DAY ONE WEDNESDAY, MARCH 27, 2019

	8.00 Registration & Networking Breakfast
	8.50 Chair's Opening Remarks Carla Greenbaum Director- Diabetes Program Benaroya Research Institute
Addressing Knowledge Gap in Immune Tolerance Induction by Connecting the Dots Between Transplantation, Allergies & Autoimmune Diseases	
Gerald (Jerry) Nepom Director Immune Tolerance Network	9.00 Antigen-Specific T Cell Profiles as Therapeutic Targets in Allergy and Autoimmune Disease - High-dimensional phenotyping identifies distinct antigen-specific T cell profiles using peripheral blood from patients with allergy and autoimmune disease - Deletion, deviation, anergy, and exhaustion are potential tolerogenic outcomes of therapy - Tracking antigen-specific T cells during therapy may be a surrogate for clinical response
David Wraith Institute Director of Immunology & Immunotherapy and Professor of Immunology University of Birmingham	9.30 Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases - A review of different approaches for induction of antigen-specific immunotherapy - A report on recent clinical trials of the approach for immunotherapy of autoimmune diseases - A discussion on the potential for combination approaches to promote antigen-specific immunotherapy
Michael Boyne VP of Product Development & Analytics Cour Pharmaceuticals	10.00 Antigen Specific Approaches to Food Allergy & Immunogenicity - Inducing tolerance without immune suppression by harnessing nanoparticle technology - Proof of principle data for Peanut Allergy - Proof of principle data for Recombinant Proteins
	10.30 Speed Networking & Morning Refreshments
Erika von Mutius Professor of Pediatric Allergology Dr. von Hauner Children's Hospital	11.30 Protection from Childhood Allergies & Inflammatory Bowel Disease - Prevention of allergic and autoimmune diseases in environment rich microbial exposure - Potential mechanisms of preventive approach - Translational aspects and considerations
Jack Ragheb Senior Medical Fellow for Immunology-Global Patient Safety Eli Lilly	12.00 Anti-Drug Antibody Responses: Past, Present & Future - Review the history of ADA responses - Review the present state of ADA responses - Discuss the future state of ADA responses



Xunrong Luo
Director-Translational Research
Duke Transplant Center, Duke University

12.30 Antigen-Specific Tolerance for Transplantation

- A top-down approach can be used to overcome the complexity of alloantigens for transplantation tolerance
- Multiple parallel mechanisms involving both innate and adaptive immune cells are implicated for transplantation tolerance
- B cells play a critical role in tolerance resistance in pre-sensitized hosts



13.00 Networking Lunch

Identification & Validation of Novel Targets & Mechanism of Actions for Antigen-Specific Immune Tolerance Induction



Antoon Van Oosterhout
VP & Head Allergic Inflammation Discovery Performance Unit
GSK

14.00 Targeting Dendritic Cells to Restore Immune Tolerance in Auto-Immune- & Allergic Diseases

- Tolerogenic dendritic cells (DCs) can induce distinct types of regulatory T-cells (Tregs)
- Induction of tolerogenic DCs that drive increased antigen-specific Tregs may restore immune tolerance in autoimmune and allergic diseases



Ranjeny Thomas
Professor of Rheumatology at University of Queensland; Director
Dendright

14.30 Antigen-Specific Tolerance Induction in Rheumatoid Arthritis

- What are the opportunities and challenges of antigen-specific tolerance induction in a systemic inflammatory autoimmune disease?
- How does the autoimmune induction phase differ from the inflammatory effector phase in rheumatoid arthritis and what are the implications for therapeutic tolerising strategies?
- What type of immunomonitoring could contribute to evaluation of the outcome of tolerising strategies in rheumatoid arthritis?



Roland Martin
Head- Department of Neuroimmunology & Multiple Sclerosis Research Neurology Clinic
University Hospital Zurich, University of Zurich

15.00 Target Identification in Immune-Mediated Disorders Including Autoimmune Diseases, Allergies, Anti-Drug Responses & Tumor Immunology

- Unbiased and systematic identification of target antigens for T cells using combinatorial chemistry and bioinformatics
- Identification of disease-relevant T cells in autoimmune diseases
- How does the autoimmune T cell response relate to recognition of foreign antigens as triggers?



15.30 Afternoon Refreshments & Poster Session

Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies



Charlotte Friert
CEO
Toleranzi AB

16.00 TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis

- TOL2 treatment modalities
- Tolerance induction and maintenance using TOL2
- Preclinical development of TOL2



Finola Moore
Associate Director of Immune Tolerance
SQZ Biotechnologies

16.30 Engineering Red Blood Cells for Immune Tolerance Using Cell Squeeze® Technology

- The SQZ process efficiently delivers antigen into red blood cells (RBCs) and primes cells for rapid clearance in the liver and spleen
- SQZ'd RBCs reduce CD4+ and CD8+ T cell responses against model antigens and human autoantigens
- SQZ'd RBCs delay or prevent onset of T1D in adoptive transfer model

17.00 Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

- What does it take to achieve a robust proof-of-concept for antigen-specific immune tolerance induction strategies in complex auto-immune mediated diseases?
- Delivering on the hype and investment thus far – how to translate promising science and clear opportunity into safe and effective antigen-specific tolerance inducing therapeutics?
- The most promising route to funding: how to secure funding, through cross-industry collaborations, to fuel early clinical trial studies and beyond?

Moderator:



Charlotte Friert
CEO
Toleranzi AB

Panelists:



Matthias von Herrath
Professor at the La Jolla Institute for Allergy & Immunology; VP of T1D R&D Center
Seattle
Novo Nordisk



David Alleva
Executive Director- Immunotherapeutics
Akston Biosciences



Joshua Sestak
President & CSO
Orion BioScience

17.30 Chair's Closing Remarks & End of Day One

Progress in immune tolerance therapies transcends individual diseases or single therapeutic platforms. We can share ideas and learn from each other in order to move forward with optimized clinical strategies and trials

Gerald (Jerry) Nepom, Director, Immune Tolerance Network

CONFERENCE DAY TWO

THURSDAY, MARCH 28, 2019

8.00 Breakfast & Networking

8.25 Chair's Opening Remarks

Jack Ragheb

Senior Medical Fellow for Immunology- Global Patient Safety

Eli Lilly

Optimization of Tolerance Delivery Systems & Translation of Antigen-Specific Tolerance Strategies into Clinic

Stephen Miller

Co-founder of Cour Pharmaceuticals;
Professor of Microbiology-Immunology
Northwestern University Medical School

8.30 Mechanisms Underlying Tolerance Induction with Antigen-Encapsulating PLG Nanoparticles

- Tolerance induction using antigen-encapsulating PLG nanoparticles (Ag-PLG) recapitulates how self-tolerance is maintained in the hematopoietic system
- Ag-PLG uptake by splenic and liver APCs confers a tolerogenic phenotype
- Ag-PLG induces the induction of CD4+Foxp3+ and CD8+CD122+ regulatory T cells

David Alleva

Executive Director-Immunotherapeutics
Akston Biosciences

9.00 Antigen-Specific Targeting of B Cells in Type 1 Diabetes

- Insulin-specific B cells promote T1D pathogenesis by acting as antigen-presenting cells (APCs) that activate pathogenic effector T cells
- Antigen-specific deletion of such B cells has not yet been successful, mainly because of the requirement of a fully-conformational antigen that contains a deletional mechanism. Akston has created such a therapeutic, AKS-107
- The presence of autoantibodies produced by autoreactive B cells allows for feasible clinical biomarker assays for both entry criteria (patient stratification) and therapeutic response monitoring

Joshua Sestak

President & CSO
Orion BioScience

9.30 Soluble Antigen Arrays' Mimic Peripheral Tolerance to Intercept Autoimmune Disease and Restore Health

- The importance of restoring tolerance mechanisms after an autoimmune break
- The role of physiochemical as well as molecular properties in therapeutic design
- The value of leveraging safety in early stage or adolescent autoimmune disease patients



10.00 Morning Refreshments & Networking

Timm Jessen

CEO
Topas Therapeutics

10.30 Preparation of Liver-Targeting Nanoparticles for Clinical Trials

- The liver as tolerance mediator
- Nanoparticles as therapeutic agents
- Regulatory aspects of nanomedicine

Matthias von Herrath

Professor at the La Jolla Institute for Allergy & Immunology; VP of T1D R&D Center
Seattle
Novo Nordisk

11.00 Obstacles for Bringing Antigenic Tolerance Induction to the Clinic

- Front runners can be chosen with smart in vivo and in vitro comparative assays
- A key obstacle for clinical development of antigenic tolerance induction is the lack of human biomarkers as surrogate endpoint in safety/dosing trials
- We do not understand how tolerance is optimally achieved in humans (regulation versus exhaustion versus anergy versus deletion)?



11.30 Networking Lunch

Fulfilling the Future of Tolerance Clinical Development with Insights from Patient Data



Kei Kishimoto
CSO
Selecta Biosciences

12.30 Preclinical & Clinical Development of Tolerogenic Nanoparticles to Mitigate Immunogenicity of Biotherapeutics

- Immunogenicity is a major cause of treatment failure for many biologic therapies
- Selecta Biosciences has developed rapamycin-carrying nanoparticles to mitigate immunogenicity to a wide variety of biologics
- An update on preclinical applications, including gene therapy, and early clinical data from a Phase 2 trial with an enzyme therapy for the treatment of severe gout



Robert (Bob) Anderson
CSO
ImmusanT

13.00 Immunotherapy for Celiac Disease Using Immuno-Dominant Gluten Epitopes (Nexvax2®) – Discovery to Phase 2

- Celiac disease, as both a food hypersensitivity and autoimmune disease, facilitates antigen challenge in patients that is enabling for epitope identification, biomarker discovery, and efficacy assessment
- The first dose effect observed when immuno-dominant gluten epitopes are administered systemically recapitulates cytokine release and symptoms caused by gluten ingestion in celiac disease
- Stepwise up dosing allows immuno-dominant gluten epitopes to be administered in a standardized regimen that uniformly achieves immune non-responsiveness to dose levels that are well above the MTD for single dose exposure



Carla Greenbaum
Director- Diabetes Program
Benaroya Research Institute

13.30 Lessons Learned from Multi-Center Trials of Antigen Therapy in T1D

- What are the specific clinical trial design considerations for multi-center trials of antigen therapy in T1D?
- How to get around the practical problems of running a multi-center GCP clinical trial?
- TrialNet observations as a solution led case study



Yoav Messinger
Medical Director- Cancer and Blood Disorders
Children's Hospitals and Clinics of Minnesota

14.00 Long-Term Consequences of Tolerance Induction Strategies Using Anti-B-Cell (Rituximab), Especially to the Growing Child: Lessons Learned from Oncology & Pompe Disease

- If immune modulation includes anti-B-cell agents, a proportion of patients exposed to Rituximab develop long-term B-cell dysfunction
- Successful tolerance induction to enzyme replacement (ERT) for infantile Pompe disease includes rituximab. However, some patients are left with ongoing IVIG requirement and long-term B-cell dysfunction
- Monitoring guidelines are suggested



14.30 Afternoon Refreshments & Networking

The Future Landscape of Antigen-Specific Immune Tolerance Therapies: The Promise of Combination Strategies



Gerald (Jerry) Nepom
Director
Immune Tolerance Network

15.00 Combining Induction with Consolidation Therapy in ITN Clinical Trials for Autoimmunity

- Induction therapy targets persistent effector cells that are a barrier to durable response
- Consolidation therapy allows homeostatic and regulatory mechanisms to mature
- Sequential combinations of induction and consolidation offer prospects for tolerogenic outcomes



15.30 Tregitopes Induce Active Tolerance in Autoimmune Diabetes & Allergy

- Tregitopes (natural T cell epitopes derived from IgG) that (a) bind to multiple MHC class II molecules, (b) suppress effector T cell responses to co-delivered antigen, and (c) up-regulate Treg-associated cytokines and chemokines
- Tregitopes promote tolerance by activating Regulatory T cell (Treg) activity and expanding Tregs in vitro and in vivo
- Tregitopes provide an explanation for the mechanism of action IVIg on DC and T-cells and may ultimately provide a safe alternative to plasma-based immune regulation therapies
- Case study on combination of Tregitope-albumin fusions and PPI peptides (T1D ASATI): Antigen-specific adaptive tolerance induction (ASATI) is induced when antigens are administered in combination with Tregitopes




16.00 Immune Modulation + Antigen Specificity: Exploring Combination Approaches for Tolerance Induction & Maintenance in Autoimmunity & Immunogenicity

- The combination of immune-modulatory agents and antigen-specific approaches may yield superior efficacy in the induction and maintenance of immune tolerance
- A review of the unmet need in autoimmunity and in the immunogenicity of therapeutic agents, as well as current attempts to address the issue
- The combination of a T cell modulator (teplizumab) and a B cell inhibitor (PRV-3279) with antigen-specific approaches will be presented as examples

16.30 Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

- What are the translational challenges of combination therapies in the context of disease complexity and mechanism of action?
- What are the regulatory guidelines and considerations for combining two unapproved drugs as a combination strategy?
- What is the expected value-split between the stakeholders?

Moderator:



Panelists:



17.00 Chair's Closing Remarks & Close of 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019

Don't miss out on the technical workshop day on next page!

PRE-CONFERENCE WORKSHOP DAY TUESDAY, MARCH 26, 2019

Workshop A

8:30am – 11:00am

Improving the Translation of Antigen Specific Therapies into the Clinic Across Disease Indications

The purpose of this workshop is to bring together experts across autoimmune fields to discuss common challenges facing clinical translation of antigen specific therapies. Topics of key relevance include defining a late stage preclinical development path of therapeutic candidates, common cross disease challenges in identifying reliable mechanistic markers of immune effects of antigen specific therapies, possible need for de-bulking therapies or other combinations to ensure success of these types of therapies, and how multiple stakeholders might come together in public-private partnership to overcome common hurdles.

Hear & Discuss About:

- Need for harmonized approaches in this space and novel ways to address them
- Blood mechanistic markers to evaluate treatment and therapeutic response of antigen specific therapies
- Improving the predictability and effective utilization of preclinical models as pre-requisites for clinical testing
- Lessons learnt from successful clinical testing of antigen specific therapies across diseases

Workshop Leaders



Julia Greenstein
VP- Research Strategy
JDRF

Julia Greenstein is the Vice President of Research Strategy at JDRF. She has been at JDRF for over 10 years beginning in the Beta cell portfolio and serving in a variety of roles in the Cure and Prevention portfolios. She has held variety of executive industry roles such as CEO of Immerge BioTherapeutics, Inc., and CSO at BioTransplant.



Simi Ahmed
Director, Research
JDRF

Simi Ahmed is a Director of Research and lead of the Immune Therapies Program at JDRF. She is responsible for creating and implementing the vision and strategy of this program, with core emphasis on the establishment of effective disease modifying immunotherapies for T1D.

Workshop B

11:30am – 14:00pm

Antigen-Specific Tolerance Induction: Robust Strategies to Improve Clinical Trials Efficacy & Success Rate

This interactive workshop session will delve deep into the challenges associated with the lack of robustness in terms of proof of concept in the field of antigen-specific immune tolerance induction, clinical efficacy in relation to mechanism of action and strategic considerations for developing clinical trial protocols to optimize successful translation into and through different phases of clinical trials.

Hear & Discuss About:

- How to document clinical efficacy in relation to mechanism of action?
- Outcome measure
- Clinical trial protocols and critical steps to consider (phase IIa as PoC component)
- Regulatory issues (advanced therapy medicinal products (ATMP) versus biological, nanoparticle)

Workshop Leader



Andreas Lutterotti
MD; Assistant Professor- Experimental Therapy Research in Multiple Sclerosis
University of Zurich

Andreas Lutterotti is Assistant Professor for “Experimental Therapy Research in Multiple Sclerosis and Other Neurological Diseases” at the University of Zurich since August 2014. His core expertise is the development and implementation of experimental therapies in the field of multiple sclerosis and other autoimmune diseases. He is Co-Founder of Cellerys AG, a company developing a cell based therapy to induce immune tolerance in MS.

Workshop C

14:30pm – 17:00pm

Considerations for Combination Strategies for Tolerizing Immunotherapies

This informative workshop highlights potential regulatory and R&D strategies to combine antigen-specific immune tolerance approaches with other therapies in order to open up the potentials to address a wider unmet patient need across various therapeutic areas.

Hear & Discuss About:

- When might combination strategies be applicable to treatment of autoimmune disease?
- What types of combination strategies might be used in autoimmune disease and is there evidence from the clinic already?
- Does combination always mean simultaneous?
- How could immunomonitoring be applied to trials of combination tolerising therapies?
- Considerations for clinical trial design
- How does the regulatory landscape change if developing a combination therapy based on two unapproved drugs?

Workshop Leaders



Amy Rosenberg

Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Amy Rosenberg received her MD from Albert Einstein College of Medicine and is Board Certified in Internal Medicine. She joined CBER, FDA in 1988, becoming Director of the Division of Therapeutic Proteins, CBER/CDER in 2000 (now DBRR3 in the Office of Biotechnology Products, CDER). She has been a driving force in risk evaluation and mitigation pertaining to the immunogenicity of therapeutic proteins and in the elucidation and implementation of immune tolerance induction protocols in clinical settings.



Ranjeny Thomas

Professor of Rheumatology at University of Queensland; Director
Dendright

Ranjeny Thomas is Professor of Rheumatology at University of Queensland as well as founder and a director of the spin-off company, Dendright, which is developing immunotherapy for autoimmune diseases. Her research seeks to understand autoimmune disease and restoration of immune tolerance. Through this work, she developed and tested the first rheumatoid arthritis vaccine.

“The development of antigen-specific tolerization is currently taking important steps, but critical questions have remained open. I see this conference as an excellent venue to exchange ideas with other investigators in this field”

Roland Martin, Head- Department of Neuroimmunology & Multiple Sclerosis Research, Neurology Clinic University Hospital Zurich, University of Zurich

BECOME A COMMERCIAL PARTNER



100+
Attendees



7+
Hours of
Networking



3
Interactive
Workshops



23+
Real World
Case Studies

Topas  Therapeutics

Brand Partner

Topas Therapeutics (Hamburg, Germany) is focused on developing products in areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas' technology induces antigen-specific regulatory T cells in the liver by mimicking bloodborne antigens via the Company's proprietary peptide-loaded nanoparticles. Topas has programs in MS, T1D and an orphan indication, which is planned to enter the clinic in 2019. The Company has collaborations with Eli Lilly and Company and with Evotec.

www.topas-therapeutics.com



Brand Partner

Orion BioScience Inc. is a preclinical stage biotechnology company focused on developing our "Soluble Antigen Array" (or SAgA) technology to intercept and prevent the onset of autoimmune diseases in at risk and early stage patients. Our research into treating multiple sclerosis, neuromyelitis optica, and type-1 diabetes has shown that Orion can develop disease specific immunotherapeutics that can re-tolerize and restore the healthy immune state. The Orion team leverages extensive development experience, and strong clinical relationships, to rapidly progress first-in-class, blockbuster treatments for NMO and T1D into the clinic

www.orionbioscience.com


NEKTAR

Brand Partner

Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates.

www.nektar.com

SENIORITY



C-Suite & VP Level

Director Level

Other

COMPANY BY TYPE

70% Large pharma & Biotech

20%

Academic institutions

10%

Technology Companies

GET INVOLVED



Bashir Langhi

Partnerships Manager

Tel: +44 (0)2031418797

Email: Bashir.Langhi@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

Web: www.as-immunetolerance.com

Tel: +1 617 455 4188

Email: register@hansonwade.com

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

- 1 Discuss and learn more about antigen-specific tolerance induction strategies with cross-disciplinary insights from the fields of transplantation, allergy and autoimmunity
- 2 Overcome challenges of delivery system optimization and robust translation into clinic through case studies focused on improvement of animal models, biomarker identification/validation studies and early clinical trial considerations
- 3 Define future scientific and strategic trends of the field with insights from clinical patient data to ensure successful antigen-specific immune tolerance drug development, both as a stand-alone approach or in combination with other strategies

SECURE YOUR PLACE

Industry Pricing	Book Before December 14, 2018 (SAVE \$800)	Standard Prices
Conference + 3 Workshops	\$3,299	\$4,099
Conference + 2 Workshops	\$2,999	\$3,799
Conference + 1 Workshop	\$2,599	\$3,399
Conference Only	\$2,099	\$2,899
Workshops (Each)	\$599	

Academic & Not-for-Profit Pricing	Book Before December 14, 2018 (SAVE \$600)	Standard Prices
Conference + 3 Workshops	\$2,199	\$2,799
Conference + 2 Workshops	\$1,999	\$2,599
Conference + 1 Workshop	\$1,699	\$2,299
Conference Only	\$1,299	\$1,899
Workshops (Each)	\$499	



VENUE

Wyndham Boston Beacon Hill
5 Blossom Street, Boston, MA 02114

For further information or assistance, please visit
www.wyndhambeaconhill.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH